Sarah Condella - Feb 25, 2022 Form 4 Insider Report for EXACT SCIENCES CORP (EXAS)

Signature
/s/ Sarah Condella by Mark R. Busch, attorney-in-fact
Stock symbol
EXAS
Transactions as of
Feb 25, 2022
Transactions value $
-$406,542
Form type
4
Date filed
3/1/2022, 05:31 PM
Previous filing
Feb 25, 2022
Next filing
Mar 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXAS Common Stock Sale -$355K -4.8K -5.44% $74.05 83.4K Feb 25, 2022 Direct F1, F2
transaction EXAS Common Stock Sale -$51.1K -680 -0.82% $75.15 82.7K Feb 25, 2022 Direct F1, F3, F4
holding EXAS Common Stock 4.92K Feb 25, 2022 Held in 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EXAS Restricted Stock Units Award $0 +15.8K $0.00 15.8K Feb 25, 2022 Common Stock 15.8K Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into in February 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.52 to $74.46, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.55 to $75.28, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
F4 In addition to the shares of Common Stock reported on this Form 4, which total 87,619 shares, Ms. Condella also holds, in the aggregate, an additional 86,779 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.
F5 Each restricted stock unit represents a contingent right to receive one share of common stock.
F6 These restricted stock units vest in four equal annual installments beginning on the first anniversary of the grant date.